[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) Form 144: This notice reports a proposed sale of 71,694 Class A shares (aggregate market value $663,065) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired through equity compensation from Amneal Pharmaceuticals on 02/27/2024 (16,950 shares), 03/01/2024 (13,776 shares) and 03/03/2024 (40,968 shares), matching the 71,694 units listed. The filing lists the total Class A shares outstanding as 314,079,309. The notice also discloses sales by the same person in the past three months: 50,000 shares sold on 08/12/2025 for $453,000 and 49,140 shares sold on 05/16/2025 for $370,542. By signing, the seller represents they possess no undisclosed material information about the issuer.

Positive

• Complete acquisition detail: acquisition dates and exact share counts are provided for each grant totaling 71,694 shares.
• Recent sale history disclosed: the filing lists prior sales of 50,000 and 49,140 shares with gross proceeds, supporting transparency.
• Broker and exchange specified: broker name and NASDAQ listing are included, clarifying execution venue.

Negative

• Insider selling activity: the filer sold a total of 99,140 shares in the past three months, which investors may view unfavorably despite small proportional impact to outstanding shares.

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing equity-compensation shares slated for market sale; disclosures are complete and specific.

The Form 144 provides clear, itemized details: acquisition dates and quantities, intended sale date, broker, and recent sales history. The amount proposed for sale (71,694 shares, $663k) is small relative to the 314,079,309 shares outstanding, suggesting limited direct dilution or market impact. The filing fulfills Rule 144 disclosure requirements and includes the usual signer representation regarding material nonpublic information.

Corporate Governance Expert

TL;DR: Disclosure is compliant and transparent; recent aggregated insider sales are notable but not materially large versus float.

The filing identifies the source of the securities as equity compensation from the issuer and specifies the broker and planned sale date. Recent dispositions of 99,140 shares in the past three months are documented, which stakeholders may note but that quantity is a small fraction of total outstanding shares. The signed representation about lack of undisclosed material information is standard and present.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
CLASS A	MERRILL LYNCH 157 CHURCH ST, FL 26 NEW HAVEN CT 06510	71694	663065.00	314079309	08/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
CLASS A	02/27/2024	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			16950	02/27/2024	EQUITY COMPENSATION
CLASS A	03/01/2024	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			13776	03/01/2024	EQUITY COMPENSATION
CLASS A	03/03/2024	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			40968	03/03/2024	EQUITY COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
NIKITA SHAH 400 CROSSING BLVD, THIRD FLOOR BRIDGEWATER NJ 08807	CLASS A	08/12/2025	50000	453000.00
NIKITA SHAH 400 CROSSING BLVD BRIDGEWATER NJ 08807	CLASS A	05/16/2025	49140	370542.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Amneal (AMRX) Form 144 report?

The Form 144 reports a proposed sale of 71,694 Class A shares (market value $663,065) to be sold around 08/14/2025 on NASDAQ.

Who acquired the shares and how were they acquired?

The shares were acquired from Amneal Pharmaceuticals through equity compensation on 02/27/2024 (16,950), 03/01/2024 (13,776), and 03/03/2024 (40,968).

Has the filer sold shares recently for AMRX?

Yes. The filing shows sales of 50,000 shares on 08/12/2025 for $453,000 and 49,140 shares on 05/16/2025 for $370,542.

How large is the proposed sale relative to outstanding shares?

The proposed sale of 71,694 shares compares to 314,079,309 Class A shares outstanding, a very small percentage of the total.

Does the filer assert possession of undisclosed material information?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.